Through treating preactivated PBMC cultures with anti-CD25 or anti-CD122 neutralizing antibodies, the data demonstrated that NK cell activation could be attenuated, while NK cell population and cytotoxicity against tumor cells could be retained (Supplementary 2 and 3), suggesting that antibody treatment might be a safer strategy for JAK inhibition. The gene discussed is IL2RB; the disease is neoplasm.